Drugs / ASTX030
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04256317 | May 2020 → Nov 2027 expected | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Taiho Oncology, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASTX030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04256317 ↗ |
| Route | Oral | “FDC Capsules for oral administration.” NCT04256317 ↗ |